Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Reverses Position On Fabre-Kramer's Gepirone, Clearing Way For Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Dispute resolution win means focus for antidepressant Travivo (gepirone extended-release) shifts to labeling, post-marketing and manufacturing despite going 2 for 12 in clinical trials.

Advertisement

Related Content

Will Alkermes Data Package Support ALKS 5461 Approval?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register